RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
GenomePrecision Technology of Beijing completed a $15 million B round, led by Yizhuang Biomedical M&A Fund. A six-year-old company, GenomePrecision develops molecular diagnostic products including precision medicine tests. Its operations include R&D, manufacturing, distribution, registration and services. The company has developed multiple series of tests for leukemia, lymphoma, transplant typing, solid tumor detection, pharmacogenomics, pathogen detection, cervical cancer products and research use.
Source: China Biotoday
